Protein-to-lipid ratio uniquely changes the rate of lysozyme aggregation but does not significantly alter toxicity of mature protein aggregates.
Amyloid
Lysozyme
Phospholipids
ROS
Toxicity
Journal
Biochimica et biophysica acta. Molecular and cell biology of lipids
ISSN: 1879-2618
Titre abrégé: Biochim Biophys Acta Mol Cell Biol Lipids
Pays: Netherlands
ID NLM: 101731727
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
21
12
2022
revised:
09
02
2023
accepted:
01
03
2023
medline:
28
3
2023
pubmed:
13
3
2023
entrez:
12
3
2023
Statut:
ppublish
Résumé
Irreversible aggregation of misfolded proteins is the underlying molecular cause of numerous pathologies, including diabetes type 2, Alzheimer's, and Parkinson's diseases. Such an abrupt protein aggregation results in the formation of small oligomers that can propagate into amyloid fibrils. A growing body of evidence suggests that protein aggregation can be uniquely altered by lipids. However, the role of the protein-to-lipid (P:L) ratio on the rate of protein aggregation, as well as the structure and toxicity of corresponding protein aggregates remains poorly understood. In this study, we investigate the role of the P:L ratio of five different phospho- and sphingolipids on the rate of lysozyme aggregation. We observed significantly different rates of lysozyme aggregation at 1:1, 1:5, and 1:10 P:L ratios of all analyzed lipids except phosphatidylcholine (PC). However, we found that at those P:L ratios, structurally and morphologically similar fibrils were formed. As a result, for all studies of lipids except PC, mature lysozyme aggregates exerted insignificantly different cell toxicity. These results demonstrate that the P:L ratio directly determines the rate of protein aggregation, however, has very little if any effect on the secondary structure of mature lysozyme aggregates. Furthermore, our results point to the lack of a direct relationship between the rate of protein aggregation, secondary structure, and toxicity of mature fibrils.
Identifiants
pubmed: 36907244
pii: S1388-1981(23)00029-X
doi: 10.1016/j.bbalip.2023.159305
pmc: PMC10405292
mid: NIHMS1921614
pii:
doi:
Substances chimiques
Muramidase
EC 3.2.1.17
Protein Aggregates
0
Amyloid
0
Lipids
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
159305Subventions
Organisme : NIGMS NIH HHS
ID : R35 GM142869
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dmitry Kurouski reports financial support was provided by Texas A&M University.
Références
Annu Rev Biochem. 2017 Jun 20;86:27-68
pubmed: 28498720
Protein Sci. 2007 May;16(5):815-32
pubmed: 17400924
Chem Phys Lipids. 2004 Jan;127(1):113-20
pubmed: 14706745
J Phys Chem Lett. 2022 May 26;13(20):4563-4569
pubmed: 35580189
Biochem J. 1983 Apr 1;211(1):155-62
pubmed: 6870819
Nat Commun. 2018 Sep 6;9(1):3609
pubmed: 30190461
J Am Chem Soc. 2014 Feb 12;136(6):2302-12
pubmed: 24484302
J Phys Chem C Nanomater Interfaces. 2022 Mar 3;126(8):4157-4162
pubmed: 35719853
Nat Chem Biol. 2015 Mar;11(3):229-34
pubmed: 25643172
Trends Cell Biol. 2020 May;30(5):341-353
pubmed: 32302547
Commun Biol. 2021 Jan 4;4(1):19
pubmed: 33398040
Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):E1994-2003
pubmed: 25855634
J Phys Chem Lett. 2022 Mar 17;13(10):2467-2473
pubmed: 35266717
Elife. 2018 Jul 03;7:
pubmed: 29969391
Biochim Biophys Acta Mol Cell Biol Lipids. 2023 Jan;1868(1):159247
pubmed: 36272517
Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):7230-7235
pubmed: 29941606
Chem Commun (Camb). 2010 Oct 14;46(38):7154-6
pubmed: 20820535
Anal Chem. 2020 May 19;92(10):6806-6810
pubmed: 32347706
J Am Chem Soc. 2007 Sep 12;129(36):11002-3
pubmed: 17705492
Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7065-70
pubmed: 27298346
ACS Nano. 2018 Jul 24;12(7):6612-6619
pubmed: 29932670
Biochim Biophys Acta. 2008 Jul-Aug;1777(7-8):794-9
pubmed: 18420023
J Biol Chem. 2003 May 9;278(19):16873-7
pubmed: 12621030
Sci Rep. 2016 Aug 08;6:31155
pubmed: 27499269
FEBS Lett. 2022 Jun;596(11):1424-1433
pubmed: 35510803
Front Cell Neurosci. 2019 May 01;13:175
pubmed: 31118888
Nat Rev Mol Cell Biol. 2008 Feb;9(2):112-24
pubmed: 18216768
J Phys Chem Lett. 2022 Sep 29;13(38):8833-8839
pubmed: 36111888
Annu Rev Phys Chem. 2011;62:279-99
pubmed: 21219138
Nat Commun. 2015 Jul 28;6:7831
pubmed: 26215704
Science. 2017 Oct 6;358(6359):116-119
pubmed: 28882996
J Phys Chem Lett. 2018 Sep 6;9(17):5125-5129
pubmed: 30133296
FEBS J. 2023 Jun;290(12):3203-3220
pubmed: 36705524
J Am Chem Soc. 2010 May 12;132(18):6324-8
pubmed: 20405832
ACS Chem Neurosci. 2022 Oct 5;13(19):2813-2820
pubmed: 36122250
J Biol Chem. 2013 Jan 25;288(4):2744-55
pubmed: 23223242
Nat Neurosci. 2019 Jul;22(7):1099-1109
pubmed: 31235907
Nat Rev Mol Cell Biol. 2018 Dec;19(12):755-773
pubmed: 30237470
Biochim Biophys Acta. 2013 Oct;1828(10):2328-38
pubmed: 23746423
NPJ Parkinsons Dis. 2019 Nov 12;5:23
pubmed: 31728405
J Parkinsons Dis. 2017;7(3):433-450
pubmed: 28671142
Front Neurosci. 2019 Apr 11;13:328
pubmed: 31031582
J Chem Phys. 2016 May 14;144(18):184901
pubmed: 27179503
Nat Rev Mol Cell Biol. 2014 Jun;15(6):384-96
pubmed: 24854788
J Am Chem Soc. 2007 Jun 6;129(22):6972-3
pubmed: 17500518
Nat Commun. 2019 Oct 29;10(1):4760
pubmed: 31664019
FASEB J. 2022 Oct;36(10):e22543
pubmed: 36094052
Analyst. 2015 Aug 7;140(15):4967-80
pubmed: 26042229
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7443-8
pubmed: 19376973
ACS Chem Neurosci. 2022 Aug 17;13(16):2483-2489
pubmed: 35930674
Biochim Biophys Acta Mol Basis Dis. 2022 Nov 1;1868(11):166485
pubmed: 35840040